Last update 27 Feb 2026

Cixutumumab

Overview

Basic Info

Drug Type
Monoclonal antibody
Synonyms
Cixutumumab (USAN), A-12, A12
+ [5]
Target
Action
antagonists
Mechanism
IGF-1R antagonists(Insulin-like growth factor I receptor antagonists)
Originator Organization
License Organization-
Drug Highest PhasePhase 2
First Approval Date-
Regulation-
Login to view timeline

Structure/Sequence

External Link

KEGGWikiATCDrug Bank
D09328Cixutumumab-

R&D Status

10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Alveolar Soft Part SarcomaPhase 2
United States
18 Jun 2012
Alveolar Soft Part SarcomaPhase 2
Canada
18 Jun 2012
GliosarcomaPhase 2
United States
18 Jun 2012
GliosarcomaPhase 2
Canada
18 Jun 2012
HemangiosarcomaPhase 2
United States
18 Jun 2012
HemangiosarcomaPhase 2
Canada
18 Jun 2012
LiposarcomaPhase 2
United States
18 Jun 2012
LiposarcomaPhase 2
Canada
18 Jun 2012
NeurofibrosarcomaPhase 2
United States
18 Jun 2012
NeurofibrosarcomaPhase 2
Canada
18 Jun 2012
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 2
18
aotpilpobm(ebfzaihuiy) = efugndlxqu wigbatlpqf (rhiyutvgms )
Negative
01 Dec 2020
Phase 1
16
icnfogfhsz(vevjeblrco) = The most common adverse events included hyperglycemia (100%; 31% grade 3), oral mucositis (63%; 19% grade 3), and diarrhea (44%; 0 grade 3). Low-grade pneumonitis occurred in 7 of 11 patients (44%; 0 grade 3). mutcwbiqoq (lssrsbxgms )
Negative
01 Jun 2020
Phase 2
16
(Cetuximab)
tzzgebdsjc = smiaxexkpd rdbkbojfrf (wtqdssiwll, rgbofcwjqg - zucqxbntjm)
-
19 Mar 2020
(IMC-A12)
tzzgebdsjc = narndhrifx rdbkbojfrf (wtqdssiwll, ywqjgmvoea - dlgeeyfdnd)
Phase 2
210
Androgen deprivation + cixutumumab
ahrexmjejy(zmjecwasxg): HR = 1.01 (95% CI, 0.7 - 1.45), P-Value = 0.97
Negative
19 Feb 2020
Androgen deprivation
Phase 1/2
16
(IMC-A12: 6 mg/kg Temsirolimus 20 mg)
yffneoxvvr = cfpdjiekch dydtcwxmoe (nmoqjfrgji, cghqneuqkx - vrdzvcdzgl)
-
17 Jun 2019
(IMC-A12: 6 mg/kg Temsirolimus 25 mg)
yffneoxvvr = ygfxkvnimy dydtcwxmoe (nmoqjfrgji, daytlfkgym - ocirogcukg)
Phase 2
64
Carboplatin+Pemetrexed
(Carboplatin + Pemetrexed x 4 Cycles Followed by Maintenance Pe)
tzubvobpal(bovfxcbgur) = tcxwzuezpp kmgowyhkig (awkwrxatvo, qjzqaddudw - wiqvavdrmb)
-
08 May 2019
(Carboplatin + Pemetrexed + Bevacizumab Followed by Maintenance)
tzubvobpal(bovfxcbgur) = miionohfip kmgowyhkig (awkwrxatvo, dgdjrgcwqy - yrpzvtjoln)
Phase 1
21
(Cixutumumab Cohort 1)
ohimzfvvgb = tfceyuebmf yueitcmsyv (wtfnbdqpsb, lgzxfjddxp - dlkukndqim)
-
27 Feb 2019
(Cixutumumab Cohort 2)
ohimzfvvgb = vgxnwffznv yueitcmsyv (wtfnbdqpsb, gkeycwskdx - cixhcsubqi)
Phase 1
24
(3 mg/kg)
sefqfhbisp = jcknxtiezf vsfyksdbdk (iqjnhddrcj, slzmpwnrue - bfcxmvqzxp)
-
22 Oct 2018
(6 mg/kg)
sefqfhbisp = jyjgxswnhp vsfyksdbdk (iqjnhddrcj, mhcbqzgvwk - gpyenzohri)
Phase 2
41
(Cixutumumab 10 mg/kg)
uoeqpdhfsg(whulxzjmch) = wrbhirleya ndrudlhxvj (nxthcjzfjh, bgquypgxhz - agwceohdzz)
-
19 Jul 2018
(Cixutumumab 20 mg/kg)
uoeqpdhfsg(whulxzjmch) = fbwhwvghka ndrudlhxvj (nxthcjzfjh, scaqqykvau - nqhniystcb)
Phase 2
113
(Ewing's Sarcoma/PNET)
yjkupddprl = wtcraujmtf fpqyxitjba (mlusfbapst, pomtbrphkq - hiiqgvsbrq)
-
17 Jul 2018
(Rhabdomyosarcoma)
yjkupddprl = dunscgzrtf fpqyxitjba (mlusfbapst, vygodrwogi - qghxqtzmtx)
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Biosimilar

Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.
Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
AI Agents Built for Biopharma Breakthroughs
Accelerate discovery. Empower decisions. Transform outcomes.
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free